Repeat	O
Nasopharyngeal	O
and	O
Throat	O
Swab	O
PCR	O

All	O
subjects	O
underwent	O
repeat	O
nasopharyngeal	O
and	O
throat	O
swab	O
PCR	O
for	O
SARS	O
-	O
CoV2	O
every	O
other	O
day	O
until	O
their	O
PCR	O
was	O
negative	O
.	O

These	O
repeat	O
PCR	O
tests	O
began	O
on	O
the	O
fifth	O
day	O
after	O
taking	O
the	O
medication	O
for	O
subjects	O
who	O
began	O
the	O
study	O
and	O
remained	O
symptom	O
-	O
free	O
.	O

The	O
PCR	O
repeat	O
testing	O
began	O
on	O
the	O
second	O
symptom	O
-	O
free	O
day	O
onward	O
for	O
subjects	O
who	O
began	O
the	O
study	O
with	O
symptoms	O
or	O
developed	O
symptoms	O
.	O

The	O
investigators	O
had	O
telephone	O
contact	O
with	O
all	O
the	O
subjects	O
every	O
three	O
days	O
throughout	O
the	O
study	O
to	O
determine	O
any	O
therapy	O
'	O
s	O
adverse	O
effects	O
.	O

A	O
re	O
-	O
evaluation	O
PCR	O
was	O
performed	O
after	O
seven	O
days	O
following	O
the	O
first	O
negative	O
PCR	O
.	O

Endpoints	O
were	O
a	O
negative	B-OtherOutcome
PCR	I-OtherOutcome
and	O
resolution	B-OtherOutcome
of	I-OtherOutcome
symptoms	I-OtherOutcome
.	O

The	O
duration	O
from	O
the	O
first	O
day	O
of	O
drug	O
intake	O
to	O
the	O
negative	O
PCR	O
was	O
counted	O
as	O
the	O
recovery	O
period	O
.	O

The	O
duration	O
from	O
the	O
first	O
day	O
of	O
drug	O
intake	O
to	O
the	O
disappearance	O
of	O
symptoms	O
was	O
counted	O
as	O
the	O
period	O
to	O
symptomatic	O
recovery	O
.	O

"	O
Adverse	B-OtherOutcome
effects	I-OtherOutcome
"	O
were	O
determined	O
by	O
the	O
existence	O
of	O
the	O
pharmacological	B-OutcomeDefinition
side	I-OutcomeDefinition
effects	I-OutcomeDefinition
of	I-OutcomeDefinition
the	I-OutcomeDefinition
particular	I-OutcomeDefinition
drug	I-OutcomeDefinition
during	I-OutcomeDefinition
treatment	I-OutcomeDefinition
.	O

A	O
detailed	O
history	O
of	O
adverse	O
effects	O
(	O
other	O
than	O
previous	O
disease	O
symptoms	O
)	O
experienced	O
by	O
each	O
participant	O
was	O
collected	O
during	O
the	O
follow	O
-	O
up	O
sample	O
collection	O
.	O

An	O
asymptomatic	O
participant	O
presented	O
with	O
no	O
symptom	O
of	O
COVID	O
-	O
19	O
and	O
remained	O
the	O
same	O
until	O
the	O
negative	O
PCR	O

